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ABSTRACT
Background: Fluticasone furoate/vilanterol (FF/VI) is
a novel once-daily (OD) inhaled corticosteroid/long-
acting b2 agonist combination in development for
chronic obstructive pulmonary disease (COPD) and
asthma.
Trial design: A multicentre, randomised, double-
blind, parallel-group, placebo-controlled study.
Methods: Participants were patients with moderate-to-
severe COPD treated with placebo or FF/VI 400/25 mg
OD for 4 weeks. Study objectives were to assess the
safety and efﬁcacy of FF/VI 400/25 mgO D
administered for 4 weeks via a novel dry powder
inhaler. Co-primary end points were change from
baseline in weighted mean (wm) heart rate 0e4h
postdose at day 28 and the incidence of adverse
events (AEs). Secondary end points included change
from baseline in trough forced expiratory volume in
one second (FEV1) (23e24 h postdose; day 29) and
wm FEV1 (0e4 h postdose; day 28). Patients were
randomised to receive FF/VI 400/25 mg or placebo in
a 2:1 ratio; all patients and investigators were blinded
to active or placebo treatment.
Results: 60 patients (mean age 64 years) were
randomised (FF/VI: n¼40; placebo: n¼20), and all
contributed data to the analysis. Mean screening post-
bronchodilator FEV1 per cent predicted was comparable
between groups (FF/VI: 58.5%; placebo: 60.1%). The
wm heart rate 0e4 h postdose was similar between
groups (difference: 0.6 beats per minute; 95% CI e3.9
to 5.1). More on-treatment AEs were reported in the
FF/VI group (68%) compared with the placebo group
(50%). The most common drug-related AEs in the FF/VI
group were oral candidiasis (8%) and dysphonia (5%).
There were no clinically relevant effects on laboratory
values, including glucose and potassium, or on vital
signs or ECGs/Holters. The FF/VI group had statistically
greater improvements compared with placebo in trough
FEV1 (mean difference 183 ml) and 0e4 h postdose
wm FEV1 (mean difference 236 ml).
Conclusion: FF/VI has a good safety and tolerability
proﬁle and improves lung function compared with
placebo in patients with COPD.
Trial registration number: clinical trials.
govdNCT00731822.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is a signiﬁcant cause of morbidity
and mortality that contributes substantially to
healthcare costs and morbidity worldwide.
1 2
Unlike other chronic diseases, it is increasing
in prevalence and is projected to be the
fourth most common cause of death world-
wide by 2030.
3 Consequently, an unmet need
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ARTICLE SUMMARY
Article focus
- Is the once-daily inhaled corticosteroid/long-
acting b2 agonist (ICS/LABA) combination FF/VI
efﬁcacious with a favourable safety and tolera-
bility proﬁle in COPD?
Key messages
- In patients with moderate-to-severe COPD, FF/VI
400/25 mg once daily improved lung function.
AEs frequently experienced with other ICS/LABA
combinations were generally reported at similar
frequencies in the placebo and active treatment
arms.
Strengths and limitations of this study
- This paper is the ﬁrst to present clinical data on
inhaled FF/VI combination therapy in patients
with chronic obstructive lung disease. Given the
4-week duration of this study, there was no end
point or surrogate marker to speciﬁcally address
the relative clinical effects of FF in COPD (such as
exacerbations), whereas the observed lung
function effects are predominantly induced by
the LABA component of the combination.
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Open Access Researchcontinues to exist for therapies directed at reducing the
morbidity and mortality of COPD.
Anti-inﬂammatory therapies administered in combi-
nation with bronchodilators according to disease severity
are a key approach by which COPD can be managed in
the long term,
4 as they target both the inﬂammation
and the bronchoconstriction that contribute to the
pathophysiology of the disease.
5e7 Long-term studies
indicate that combination therapies consisting of
a bronchodilatory long-acting b2 agonist (LABA) plus an
anti-inﬂammatory inhaled corticosteroid (ICS) in one
inhaler have the potential to modify disease progression
through positive effects on lung function, symptoms and
exacerbations.
8e12
Current ICS/LABA combinations are dosed twice
daily; however, once-daily treatment has the potential to
simplify treatment in chronic disease such as COPD by
reducing dosing frequency.
13 Vilanterol (VI) and ﬂuti-
casone furoate (FF) are, respectively, a novel inhaled
LABA and ICS in development for once-daily combina-
tion therapy for COPD and asthma. VI is an antedrug
analogue of salmeterol with a higher intrinsic activity at
the b2 receptor than salmeterol.
14 In vitro, VI exhibits
>1000 fold selectivity for b2 receptors relative to b1 or b3
receptors,
15 while data from human lung tissue indicate
a faster onset and longer duration of action (22 h) than
salmeterol.
16 FF is chemically distinct from ﬂuticasone
propionate (FP) in that the 17a-ester of the ﬂuticasone
moiety comprises a furoate, as opposed to propionate
group; this group is not cleaved from the molecule
during metabolism.
17 In vitro, studies of FF suggest
a pharmacological proﬁle that differs from FP and other
ICS; FF exhibits greater potency in cell culture models of
inﬂammation compared with FP and budesonide, shows
greater potency compared with FP in peripheral blood
mono-nuclear cells from patients with mild asthma or
moderate/severe COPD and is further differentiated
from FP in that cell culture assays of glucocorticoid-
dependent gene expression and glucocorticoid receptor
nuclear translocation indicate activity at >24 h, which is
not observed with FP.
18 Clinically, preliminary results in
patients with COPD have demonstrated that VI is well
tolerated with a good safety proﬁle.
19 20
This is the ﬁrst study to report on the clinical effects of
the combination of FF/VI in patients with obstructive
lung disease. The aim was to assess the short-term safety,
tolerability and efﬁcacy of FF/VI in patients with COPD,
with a primary focus on safety; efﬁcacy was a secondary
end point. Preliminary results from this study have been
presented in abstract form.
21
METHODS
Patients
The study was conducted between August 2008 and
February 2009 at nine centres in two countries (Norway
and Sweden). To be eligible, patients were required to
be aged between 40 and 80 years, exhibiting a clinical
history of COPD, have a smoking history of $10 pack-
years, a post-bronchodilator forced expiratory volume in
one second (FEV1)/forced vital capacity ratio of #0.70
and a post-bronchodilator FEV1 $40% and #80%
predicted (GOLD stage II/III).
Patients were allowed ipratropium bromide for use as
rescue medication during the screening period and
throughout the study treatment period. Other permitted
medications during the screening and the treatment
periods included: intranasal sodium cromoglycate or
nedocromil sodium, mucolytics, antibiotics (for short-
term treatment of acute non-respiratory tract infections),
antihistamines, cough suppressants (for short-term treat-
ment #7 days), intranasal corticosteroids (patients were
tobeonastable,dailydoseforatleast4 weekspriortovisit
1 and throughout the study); topical or ophthalmic
corticosteroids.
Medications prohibited prior to and during the study
included: depot corticosteroids (12 weeks prior to
screening); systemic, oral or parenteral corticosteroids
(6 weeks prior to screening); p-glycoprotein inhibitors
(6 weeks prior to screening); cytochrome P450 3A4
strong inhibitors (6 weeks prior to screening); ICS alone
or in combination with a LABA (4 weeks prior to
screening); tiotropium (1 week prior to screening);
theophyllines, LABA (oral and inhaled) and oral leuko-
triene inhibitors (48 h prior to screening); inhaled
sodium cromoglycate or nedocromil sodium (24 h prior
to screening); ipratropium/albuterol combination prod-
ucts and short-acting b2 agonists (6 h prior to screening);
diuretics; monoamine oxidase inhibitors; b receptor
antagonists; anticonvulsants and phenothiazines; tricyclic
antidepressants.
Patients were excluded if they exhibited: any respira-
tory disorder other than COPD; poorly controlled COPD
deﬁned as having acute worsening (patient-managed
corticosteroid or antibiotic treatment or physician
prescription) within 6 weeks of the study or a hospital-
isation for COPD within 12 weeks; a lower respiratory
tract infection requiring treatment with antibiotics
within 6 weeks of the study; requirement for daily long-
term oxygen therapy ($12 h/day). No exclusion criteria
were imposed based on reversibility to 400 mg albuterol
administered via metered-dose inhaler. According to the
study protocol, reasons for withdrawal from the study as
recorded in the electronic Case Report Form included:
adverse event (AE), lack of efﬁcacy, protocol deviation,
lost to follow-up, investigator discretion, withdrawal of
consent, patient met any of the liver chemistry stopping
criteria, patient provided a positive serum pregnancy test
or was repeatedly non-compliant (<80%) with study
medication. Patients could also be withdrawn from
the study if any of the following criteria were met:
COPD exacerbation (deﬁned as worsening of COPD
symptoms requiring the use of any treatment other than
study medication or rescue ipratropium); clinically
important changes in laboratory parameters; pneumonia
(conﬁrmed by chest x-ray within 48 h of diagnosis);
Electrocardiogram (ECG) abnormalities including
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(bpm) or an increase on heart rate from baseline of
$40 bpm (two measure $5 min apart), prolongation in
absolute QTc(B(Bazett’s formula)) to >500 ms (>600 ms
uncorrected QTc; conﬁrmed by three readings $5m i n
apart on $3 ECGs), ventricular rate <37 bpm
(conﬁrmed by three readings $5 min apart on $3
ECGs), PR interval >240 ms (conﬁrmed by three read-
ings $5 min apart on $3 ECGs), pathological Q waves,
non-speciﬁc intraventricular conduction delay, ST-T wave
abnormalities (excluding non-speciﬁc ST-T wave abnor-
malities), right or left complete bundle branch block.
All patients gave written informed consent, and the
protocol was approved by the appropriate institutional
review boards and conducted in accordance with good
clinical practice guidelines and the 1996 version of the
Declaration of Helsinki.
Study design
This was a 4-week, multicentre, randomised, placebo-
controlled, parallel-group study (GSK study number
HZC111348; clinical trials.gov NCT00731822). Patients
entered a #7-day screening period to collect baseline
safety data and to determine eligibility; eligible patients
were then randomised 2:1 to inhaled FF/VI combination
(400/25 mg) or placebo administered once daily in the
morning by a novel dry powder inhaler (NDPI; Glaxo-
SmithKline, London, UK). This was a double-blind study.
Neither the subject nor the investigator knew which study
medication the subject was receiving; the NDPI devices
containing active medication or placebo appeared
identical to the patient, their caregivers and the investi-
gator, and the placebo dry powder formulation was
indistinguishable from the FF/VI inhalation powder
formulation. The central randomisation schedule was
generated by the sponsor using a validated computerised
system (RandAll). Patients were randomised using
the Registration and Medication Ordering System
(RAMOS), an automated interactive telephone-based
system that was used by the investigator or designee to
register the patient, randomise the patient and receive
medication assignment information. Patients were
eligible to be randomised provided none of the following
occurred between visit 1 (screening) and visit 2
(randomisation): COPD exacerbation or lower respira-
tory tract infection; abnormal clinically signiﬁcant ﬁnd-
ings including liver chemistry, biochemical, haematology
or urinalysis screening tests; evidence of active, clinically
signiﬁcant abnormalities in 24-h Holter ECG at screening
or predose 12-lead ECG at visit 2; evidence of non-
compliance with prohibited medications and keeping
clinic visit appointments. Post-randomisation, patients
were reviewed at days 2, 7 (telephone contact), 14, 15, 28
and 29. All visits occurred in the morning with visits on
days 2, 15 and 29 needing to occur within 22 h following
study medication administration to obtain the 23e24-h
postdose trough FEV1 measurement. Patients withheld
study medication on the morning of clinic visits and
rescue medication for at least 6 h prior to clinic visits.
A patient who had been assigned a patient identiﬁer
and had completed at least one study procedure (in
addition to signing a consent form) but had not met
inclusion or randomisation criteria to enter the treat-
ment period or who did meet the exclusion criteria was
classiﬁed as a screening failure.
The 400 mg dose of once-daily FF was chosen as
this dose had been previously assessed for up to
8 weeks in studies of FF monotherapy in patients with
asthma and had no clinically signiﬁcant effect on the
hypothalamicepituitaryeadrenal axis.
22e25 VI at 25 mg
has demonstrated sustained bronchodilation in prelim-
inary studies in patients with COPD.
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Outcome measurements
The co-primary safety end points were the change from
baseline in supine (lying down with head upward)
weighted mean heart rate 0e4 h postdose at the end of
the 28-day treatment period and the incidence of AEs
throughout. Heart rate was assessed using standardised
ambulatory monitors (Omron HEM-711DLX device
(Omron Healthcare Inc. Kyoto, Japan) supplied by
Biomedical Systems (Brussels, Belgium, and Maryland
Heights, Missouri, USA)) throughout the study to
ensure accuracy and consistency of data recorded. Vital
signs were collected predose and at 15, 45, 90 min and 2
and 4 h postdose on days 1, 14 and 28 and predose for all
other visits. AEs (coded using the Medical Dictionary for
Regulatory Authorities) were assessed during each clinic
visit. Each patient was provided with a ‘medical prob-
lems/medications taken diary’ in which they were
instructed to record any medical problems that they
experienced and any medications used to treat the
medical problem(s). The investigator or designee
reviewed the diary at each clinic visit, and all conﬁrmed
AEs/serious AEs were recorded in the electronic Case
Report Form.
Other safety end points included weighted mean and
maximum systolic blood pressure and mean arterial
blood pressure and weighted mean and minimum dia-
stolic blood pressure over 0e4 h on days 1, 14 and 28.
Weighted mean glucose and potassium over 0e4ho n
days 1, 14 and 28 and maximum glucose and minimum
potassium were other safety end points. Weighted mean
and maximum QTc(F) (QT interval corrected by
Fridericia’s method) and QTc(B) (QT interval corrected
by Bazett’s method) derived from 12-lead ECGs
recorded predose and 30 min and 1, 2 and 4 h postdose
on days 1, 14 and 28, changes in haematologic and
clinical chemistry parameters on days 14 and 28
and 24-h, 3-lead Holter ECG measurements at screening
and day 28 were additional safety end points. Stand-
ardised ECG (PCECG 1200M ECG machine) and 3-lead
Holter devices (DATRIX DR512 VX3 (Biomedical
Systems, Brussels, Belgium, and Maryland Heights,
Missouri, USA)) were used throughout the study, with
central reader over-reads performed (representative
from Biomedical Systems) to ensure consistency and
accuracy of data recorded. Collection supplies for blood
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and haematology analytes and the pharmacodynamic
assessments of plasma glucose and serum potassium
levels) and urine collection supplies and sample analyses
were provided by a central laboratory (Quest Diagnostics
Clinical Trials (Heston, Middlesex, UK)). The incidence
of COPD exacerbations was also recorded throughout
the study. Each patient was provided with an electronic
peak ﬂow meter (Micro Medical MicroDiary electronic
peak ﬂow meter provided by Biomedical Systems,
Brussels, Belgium), which the patient used to measure
their peak expiratory ﬂow three times, twice daily, in
the morning and evening from screening to the end of
4-week treatment period.
Secondary efﬁcacy end points were assessed by clinic
spirometry. All sites used standardised spirometric
equipment (Vitalograph Centralized Spirometry System
(Biomedical Systems, Brussels, Belgium, and Maryland
Heights, Missouri, USA)), and data were over-read by
a trained over-reader (representative from Biomedical
Systems) to ensure consistency and accuracy of collected
data. Secondary efﬁcacy end points were change from
baseline in trough clinic visit FEV1 (23e24 h postdose)
on days 2, 15 and 29 (to assess the 24 h effect of VI and
to evaluate the contribution of FF) and weighted mean
FEV1 (0e4 h postdose) on days 1 and 28 (to evaluate the
contribution of VI). Trough FEV1 was deﬁned as the
mean of the FEV1 values obtained 23 and 24 h after
dosing on days 1, 14 and 28. Other end points included
time to an increase of $100 ml above baseline in FEV1
on day 1 (0e4 h), peak FEV1 on days 1 and 28 (0e4h )
and serial FEV1 and forced vital capacity on days 1 and
28 (to evaluate the contribution of VI).
Statistical analysis
The sample size of 60 evaluable patients was based on the
co-primary end point of change from baseline in
weighted mean heart rate 0e4 h postdose at the end of
the 28-day treatment period. The expected variability
used for the sample size calculations in this study was
based on data from a previous COPD study (B2C108562)
with the compound GW642444H (data not shown),
which demonstrated between-patient estimates of stan-
dard deviation (SD) of up to 10 bpm for change from
baseline weighted mean heart rate. The residual SD from
the corresponding statistical analyses was in the range of
7.2e8.0 bpm. In the current study, weighted mean heart
rate was calculated from heart rate recorded at clinic
visits and so a more conservative estimate of SD of
10 bpm was used for the sample size calculations. FF/VI
was considered non-inferior to placebo for heart rate if
the upper limit of the 95% CI for the estimated treatment
difference for weighted mean heart rate was less than
+10 bpm. The true difference between placebo and FF/
VI was assumed to be 0 bpm. The number of completers
in the B2C108562 study was 17 in the placebo group and
34 in the GW642444H group; therefore, if a similar
number of patients completed the current study, there
would be a 90% power to show non-inferiority to placebo.
To allow for a possible withdrawal rate of 15%, 20 patients
were randomised to placebo and 40 to FF/VI.
All efﬁcacy and safety analyses used the intent-to-treat
(ITT) population, deﬁned as all randomised patients
who received at least one dose of study medication. The
primary analysis was performed for the ITT population
using a Repeated Measures Mixed Model for weighted
mean heart rate 0e4 h postdose on days 1, 14 and 28
(visits 2, 5 and 7). A one-sided 2.5% risk associated with
incorrectly rejecting the null hypothesis (signiﬁcance
level) was considered acceptable for this study. As this
was a single comparison, and there was no planned
formal statistical analysis for the AE data, no adjustment
was made for multiplicity.
Pair-wise comparisons between FF/VI and placebo
were performed for all secondary efﬁcacy end points and
other key end points using Repeated Measures Mixed
Models for the ITT population.
RESULTS
Of 89 patients screened, 60 were randomised and
comprised the ITT population. The reasons for
screening failure were failure to meet inclusion/exclu-
sion criteria (n¼16), failure to meet randomisation
criteria (n¼8) and withdrawal of consent (n¼5). Details
of patient disposition and reasons for discontinuation
are shown in ﬁgure 1, and patient baseline characteris-
tics are shown in table 1.
The history of COPD was similar across the treatment
groups, with the majority of the ITT population (87%)
Enrolment
Assessed for eligibility (n=89)
Randomised (n=60)
Randomised  to FF/VI 
400/25  g (n=40)
Received FF/VI         
400/25 µg (n=40)
Randomised  placebo (n=20)
Received placebo (n=20)
Discontinued placebo (n=4)
Adverse event (n=2)
Protocol deviation (n=1)
Lost to follow-up (n=1)
Discontinued FF/VI 
400/25  g (n=1)
Adverse event (n=1)
Analysed (n=40) Analysed (n=20)
Excluded (n=29)
Withdrawal of consent (n=5)
Randomisation
Treatment
Follow-up
Analysis
Not meeting entry criteria (n=24)
Figure 1 Patient disposition and reasons for discontinuation
for the ﬂuticasone furoate (FF)/vilanterol (VI) (400/25 mg) and
placebo treatment groups.
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Efﬁcacy and safety of FF/VI once daily in COPDhaving a COPD diagnosis of <10 years. Smoking history
was similar across the treatment groups, with 37% of the
overall ITT population being current smokers (40% in
the placebo group and 35% in the FF/VI group). During
the run-in period, 11 patients (55%) in the placebo
group and 15 patients (38%) in the FF/VI group used
COPD medication. Short-acting bronchodilators (ipra-
tropium bromide/salbutamol) were the most frequently
used medications; ICS/LABA combination therapy was
used by one patient (5%) in the placebo group and by
two patients (6%) in the FF/VI group. Eight patients
(40%) in the placebo group and 14 patients (35%) in
the FF/VI group were taking concomitant COPD medi-
cation during the treatment period. The most common
medication was ipratropium bromide, taken by six
patients (30%) in the placebo group and by 11 patients
(28%) in the FF/VI group. The mean treatment expo-
sure was similar across the two treatment groups,
with 80% of patients in each group exposed to study
treatment for between 28 and 30 days.
Safety
There was no statistically signiﬁcant difference in the
adjusted mean change from baseline in weighted mean
heart rate 0e4 h postdose between the FF/VI and
placebo groups (+0.7, +0.8 and +0.6 bpm on days 1, 14
and 28, respectively). FF/VI was non-inferior to placebo
as the upper CI was below the predeﬁned non-inferiority
limit of +10 bpm. Figure 2 shows adjusted mean change
from baseline for postdose 0e4 h weighted mean heart
rate for FF/VI and placebo at days 1, 14 and 28.
There were no statistically signiﬁcant differences
between the FF/VI and placebo groups on maximum
heart rate, weighted mean systolic blood pressure or
maximum systolic blood pressure as the 95% CI for all
differences contained zero (table 2).
For the weighted mean diastolic blood pressure and
minimum diastolic blood pressure, there was no consis-
tent evidence of a treatment effect. On both days 1 and
28, the 95% CI values for the mean change from base-
line in these two parameters included zero, indicating
no difference from placebo. On day 14, the 95% CI
values did not include zero, suggesting a difference from
placebo (table 2). The changes from baseline in the
weighted mean for the mean arterial blood pressure
were minimal and similar between the placebo and FF/
VI groups on days 1, 14 and 28.
The number and proportion of patients who reported
an AE while receiving study treatment was 27 (68%) in
the FF/VI group and 10 (50%) in the placebo group. Of
these patients, nine (23%) in the FF/VI group and
two (10%) in the placebo group experienced AEs
considered to be possibly related to the study drug.
Nasopharyngitis was the most common on-treatment
AE reported in both the placebo and the FF/VI groups
(three (15%) patients in placebo group and seven
(18%) patients in FF/VI group). The most frequent
on-treatment AEs are shown in table 3. Oral candidiasis
and dysphonia were the most common drug-related
AEs reported in the FF/VI group (three patients (8%)
and two patients (5%), respectively). No deaths were
Table 1 Patient demographics (intent-to-treat population)
Placebo (N[20) FF/VI 400/25 mg( N [40) Total (N[60)
Age (years), mean (SD) 63.8 (6.01) 63.5 (7.10) 63.6 (6.71)
Male, n (%) 15 (75) 25 (63) 40 (67)
Race: white, n (%) 20 (100) 40 (100) 60 (100)
Height (cm), mean (SD) 174.6 (6.64) 174.1 (8.11) 174.3 (7.60)
Weight (kg), mean (SD) 82.44 (16.276) 78.66 (14.169) 79.92 (14.875)
Pre-bronchodilator FEV1 (l), mean (SD) 1.710 (0.4118) 1.628 (0.4817) 1.655 (0.4577)
Post-bronchodilator FEV1 (l), mean (SD) 1.939 (0.4454) 1.860 (0.4747) 1.886 (0.4629)
Post-bronchodilator per cent predicted FEV1*
(%), mean (SD)
60.1 (10.86) 58.5 (10.03) 59.1 (10.25)
Per cent reversibility in FEV1 (%), mean (SD) 14.5 (12.48) 16.2 (14.14) 15.6 (13.53)
Post-bronchodilator FEV1/FVC, mean (SD) 55.3 (8.41) 52.7 (8.68) 53.6 (8.61)
*FEV1 calculated using Third National Health and Nutrition Examination Survey (NHANES III) values.
FEV1, forced expiratory volume in one second; FF, ﬂuticasone furoate; FVC, forced vital capacity; VI, vilanterol.
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Figure 2 Adjusted mean change from baseline in weighted
mean (wm) heart rate 0e4 h postdose on days 1, 14 and 28
(intent-to-treat population). FF, ﬂuticasone furoate; VI,
vilanterol.
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Efﬁcacy and safety of FF/VI once daily in COPDreported. One non-fatal serious AE (ulcerative colitis)
was reported in the FF/VI group by a patient with
a medical history of ulcerative colitis. The study investi-
gator considered that there was no reasonable possibility
that the ulcerative colitis may have been caused by the
investigational drug. Withdrawals due to AEs were low in
both the FF/VI group (n¼1 patient: diverticulum) and
the placebo group (n¼2 patients: an abnormal ECG
(considered to be treatment related) and urinary tract
infection). No COPD exacerbations were experienced in
either treatment group.
A small statistically signiﬁcant increase (0.32 mmol/l;
95% CI 0.10 to 0.53) with FF/VI versus placebo was
observed on day 28 (but not on days 1 and 14) for
change from baseline in weighted mean plasma
glucose FF/VI (ﬁgure 3A). No statistically signiﬁcant
difference was seen between the treatment groups for
the change from baseline in weighted mean potassium
(ﬁgure 3B). Mean QTc(F(Fridericia’s correction))
intervals predose on day 1 were similar between the
placebo and FF/VI groups (398 and 392 ms, respec-
tively). The mean changes from baseline in QTc(F) at
days 1, 14 and 28 were small and ranged from e2.9 to
3.2 ms in the placebo group and from e5.9 to 3.6 ms
in the FF/VI group (ﬁgure 4). For weighted and
maximum 0e4 h QTc(F), no signiﬁcant treatment
difference in adjusted mean change was observed at
any time point between treatments. All patients in both
treatment groups had maximum postdose QTc(F)
intervals of #450 ms.
There were also no apparent trends for a treatment
effect on premature ventricular beats, supraventricular
beats or ventricular runs, as measured by a 3-lead Holter
device. No clinically relevant treatment effects were
observed on laboratory parameters. Results for AM and
PM peak expiratory ﬂow during the screening and study
periods (days 1e28) are shown in table 4.
Efﬁcacy
The 95% CI values for the adjusted mean difference
between placebo and FF/VI in change from baseline
in trough FEV1 on days 2, 15 and 29 all excluded zero
(table 5), indicating a statistically signiﬁcant improve-
ment in trough FEV1 with FF/VI compared with placebo.
Adjusted mean change from baseline trough FEV1 values
for FF/VI and placebo on days 2, 15 and 29 is shown in
ﬁgure 5A.
Table 2 Adjusted mean differences from PBO (95% CI), safety analysis (intent-to-treat population)
Change from baseline maximum heart rate (bpm) (0e4h )
Day 1 (PBO, n¼20; FF/VI 400/25 mg, n¼40) 1.4 (e3.1 to 5.9)
Day 14 (PBO, n¼16; FF/VI 400/25 mg, n¼39) 1.9 (e3.4 to 7.3)
Day 28 (PBO, n¼16; FF/VI 400/25 mg, n¼39) 3.2 (e2.5 to 8.8)
Change from baseline in weighted mean systolic blood pressure (mm Hg) (0e4h )
Day 1 (PBO, n¼20; FF/VI 400/25 mg, n¼40) e0.1 (e5.4 to 5.3)
Day 14 (PBO, n¼16; FF/VI 400/25 mg, n¼39) e2.2 (e7.9 to 3.4)
Day 28 (PBO, n¼16; FF/VI 400/25 mg, n¼39) 0.3 (e6.2 to 6.8)
Change from baseline in maximum systolic blood pressure (mm Hg) (0e4h )
Day 1 (PBO, n¼20; FF/VI 400/25 mg, n¼40) e1.0 (e7.4 to 5.5)
Day 14 (PBO, n¼16; FF/VI 400/25 mg, n¼39) e2.9 (e9.0 to 3.3)
Day 28 (PBO, n¼16; FF/VI 400/25 mg, n¼39) 0.9 (e5.9 to 7.8)
Change from baseline in weighted mean diastolic blood pressure (mm Hg) (0e4h )
Day 1 (PBO, n¼20; FF/VI 400/25 mg, n¼40) e2.1 (e4.6 to 0.4)
Day 14 (PBO, n¼16; FF/VI 400/25 mg, n¼39) e3.6 (e6.7 to e0.5)
Day 28 (PBO, n¼16; FF/VI 400/25 mg, n¼39) e1.4 (e5.1 to 2.4)
Change from baseline in minimum diastolic blood pressure (mm Hg) (0e4h )
Day 1 (PBO, n¼20; FF/VI 400/25 mg, n¼40) e2.3 ( 5.2 to 0.6)
Day 14 (PBO, n¼16; FF/VI 400/25 mg, n¼39) e5.2 (e8.8 to e1.6)
Day 28 (PBO, n¼16; FF/VI 400/25 mg, n¼39) e2.7 (e7.4 to 1.9)
Population sizes for each day and each time point relate to the number of patients with analysable data at the given time point.
bpm, beats per minute; FF, ﬂuticasone furoate; PBO, placebo; VI, vilanterol.
Table 3 On-treatment adverse events experienced by
$5% of patients in any treatment group (intent-to-treat
population)
Adverse event,
n (%)
Placebo
(N[20)
FF/VI 400/25 mg
(N[40)
Any event 10 (50) 27 (68)
Nasopharyngitis 3 (15) 7 (18)
Headache 1 (5) 6 (15)
Dizziness 1 (5) 2 (5)
Oral candidiasis 0 3 (8)
Dysphonia 0 2 (5)
Chest pain 1 (5) 1 (3)
Dry mouth 1 (5) 0
Dyspnoea 1 (5) 0
ECG abnormal 1 (5) 0
Erythema 1 (5) 0
Hyperhidrosis 1 (5) 0
Myalgia 1 (5) 0
Fever 1 (5) 0
Rash 1 (5) 0
Urinary tract infection 1 (5) 0
FF, ﬂuticasone furoate; VI, vilanterol.
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Efﬁcacy and safety of FF/VI once daily in COPDSimilarly, adjusted mean treatment differences in
change from baseline in weighted mean FEV1 (0e4h )
on days 1 and 28 showed statistically greater improve-
ments of FEV1 in the FF/VI group relative to placebo
(table 5). Adjusted mean change from baseline weighted
mean (0e4 h) FEV1 values for FF/VI and placebo on
days 1 and 28 is shown in ﬁgure 5B. The adjusted mean
treatment differences in change from baseline in 0e4h
serial FEV1 on days 1 and 28 were higher for the FF/VI
group compared with the placebo group at all
time points; the CIs did not include zero, indicating
a statistically signiﬁcant difference across the time points
(table 6 and ﬁgure 6). The majority (65%) of patients in
the FF/VI group achieved a $100 ml increase from
baseline FEV1 at the 5 min postdose time point on day 1,
the ﬁrst postdose time point at which FEV1 was
measured, compared with 10% in the placebo group. By
the 4 h postdose time point, 85% of patients in the FF/
VI group and 50% of patients in the placebo group had
achieved a $100 ml increase from baseline (table 7).
The mean changes from baseline in peak FEV1 (0e4h
postdose) were higher on both days 1 and 28 for the
FF/VI group (315 and 348 ml, respectively) compared
with the placebo group (98 and 119 ml, respectively).
DISCUSSION
This paper is the ﬁrst to present clinical data on inhaled
FF/VI combination therapy in patients with chronic
obstructive lung disease. FF/VI, dosed once daily, did
not affect heart rate, had an on-treatment AE proﬁle
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Figure 3 Adjusted mean change from baseline (0e4h )
weighted mean (wm) glucose (A) and potassium (B) (intent-to-
treat population). FF, ﬂuticasone furoate; VI, vilanterol.
Figure 4 Adjusted mean change from baseline in weighted
mean (wm) QTc(F) (0e4 h) (intent-to-treat population). FF,
ﬂuticasone furoate; VI, vilanterol.
Table 4 Summary results for AM and PM PEF (screening period and days 1e28)
Daily PEF, l/min, mean (SD) PBO (N[20) FF/VI 400/25 mg( N [40)
AM
Screening (PBO, n¼19; FF/VI 400/25 mg, n¼39) 310.4 (75.88) 290.4 (107.59)
Days 1e28 (PBO, n¼20; FF/VI 400/25 mg, n¼40) 295.0 (77.89) 318.3 (97.84)
PM
Screening (PBO, n¼17; FF/VI 400/25 mg, n¼37) 318.8 (82.84) 308.1 (101.11)
Days 1e28 (PBO, n¼20; FF/VI 400/25 mg, n¼40) 303.7 (79.17) 337.0 (101.69)
Population sizes for each day and each time point relate to the number of patients with analysable data at the given time point.
FF, ﬂuticasone furoate; PBO, placebo; PEF, peak expiratory ﬂow; VI, vilanterol.
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Efﬁcacy and safety of FF/VI once daily in COPDcurrently known to be associated with ICS therapy and
showed clinical efﬁcacy compared with placebo.
The results of the safety evaluation of this study
suggest that FF/VI has a clinically acceptable safety
proﬁle at the given dose (400/25 mg once daily).
Previous studies of other twice-daily LABAs in both
patients and healthy volunteers have shown that they can
be associated with b2-mediated systemic adverse effects
such as headache, palpitations with changes in heart
rate, prolongation of the QTc interval and increased
glucose and/or decreased potassium blood levels.
27e29
Consequently, these parameters were investigated in this
study. The lack of difference between the FF/VI and
placebo groups in the adjusted mean change from
baseline in weighted mean heart rate 0e4 h postdose
provides strong evidence of a lack of clinical effect of
FF/VI on heart rate. There was also no evidence of
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Figure 5 Adjusted mean change from baseline in (A) trough
forced expiratory volume in one second (FEV1) at days 2, 15
and 29, and (B) weighted mean (wm) (0e4 h) FEV1 on days 1
and 28 (intent-to-treat population). FF, ﬂuticasone furoate; VI,
vilanterol.
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Efﬁcacy and safety of FF/VI once daily in COPDclinically relevant treatment effects in the ECG assess-
ments, including dysrhythmias. The absence of detri-
mental cardiovascular incidents in this study suggests
that the risk of adverse cardiovascular effects with FF/VI
is low. Longer term studies in substantially larger cohorts
of patients with COPD would be required to determine
whether any subgroup of patients with COPD may be at
higher risk of developing cardiac side effects. Neverthe-
less, given that cardiovascular diseases are more preva-
lent in patients with COPD
30 and there is an ongoing
discussion related to the cardiac safety of many COPD
therapies,
31e33 it is notable that no cardiac safety signal
was detected in this study. No clinically relevant treat-
ment effects on haematology, clinical chemistry or
urinalysis were observed. A statistically signiﬁcant
difference between FF/VI and placebo was observed at
day 28 (but not on days 1 and 14) for weighted mean
plasma glucose; this difference was driven by a decrease
in the mean change from baseline in plasma glucose in
the placebo group (see ﬁgure 3A) rather than an
increase in plasma glucose in the FF/VI group.
The proportion of patients experiencing one or more
on-treatment AEs was higher in the FF/VI group (68%)
compared with the placebo group (50%), and these
events were primarily accounted for by AEs commonly
reported with ICS treatment (nasopharyngitis and oral
candidiasis). Dysphonia, an expected AE with ICS treat-
ment, was observed at the incidence of 5% in the FF/VI
group and was not observed in the placebo group. No
COPD exacerbations were reported during the study.
The results of the secondary efﬁcacy analysis showed
a signiﬁcant improvement in FEV1 relative to placebo
with FF/VI treatment. A treatment difference of 183 ml
in trough FEV1 measured 23e24 h postdose was
observed on day 29, showing a 24-h duration of effect for
this combination. This improvement was greater than
the 100e140 ml outcome recently suggested to be of
a minimal important difference in clinical trials of
COPD.
34 Serial measurements of FEV1 on day 1 showed
a rapid onset of action for FF/VI compared with
placebo. Clinically relevant bronchodilation ($100 ml)
was observed at the 5-min postdose time point following
the ﬁrst dose (the earliest postdose assessment time
point in this study) in most patients receiving FF/VI.
A sustained 24-h effect is advantageous in the treat-
ment of patients with COPD, providing it is not accom-
panied by a loss in efﬁcacy during chronic dosing, as
could be seen if tolerance to the bronchodilating effect
was induced. Mean changes from baseline in maximal
weighted mean FEV1 observed 0e4 h postdose were
Table 6 Serial changes in lung function 0e4 h postdose forced expiratory volume in one second (l) on days 1 and 28
LS mean
change from
baseline (SE)
Day 1 Day 28
Placebo FF/VI Tx Diff (95% CI) Placebo FF/VI Tx Diff (95% CI)
Predose ee e0.022 (0.0365) 0.223 (0.0234) 0.201
(0.113 to 0.288)
5 min 0.009 (0.0219) 0.140 (0.0151) 0.131
(0.077 to 0.184)
0.038 (0.0370) 0.254 (0.0237) 0.216
(0.127 to 0.305)
15 min 0.038 (0.0282) 0.187 (0.0199) 0.149
(0.080 to 0.219)
0.055 (0.0390) 0.279 (0.0249) 0.224
(0.130 to 0.317)
30 min 0.026 (0.0273) 0.205 (0.0193) 0.179
(0.112 to 0.246)
0.054 (0.0402) 0.278 (0.0256) 0.225
(0.129 to 0.321)
60 min 0.025 (0.0265) 0.213 (0.0186) 0.188
(0.123 to 0.253)
0.071 (0.0382) 0.297 (0.0243) 0.226
(0.135 to 0.317)
120 min 0.028 (0.0285) 0.235 (0.0202) 0.207
(0.137 to 0.277)
0.063 (0.0361) 0.285 (0.0231) 0.222
(0.135 to 0.308)
240 min  0.003 (0.0358) 0.261 (0.0253) 0.265
(0.176 to 0.353)
0.052 (0.0394) 0.278 (0.0252) 0.226
(0.132 to 0.321)
FF, ﬂuticasone furoate; LS, least squares; Tx, treatment; VI, vilanterol.
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Figure 6 Least squares mean change from baseline in serial
forced expiratory volume in one second (FEV1) on days 1 and
28 (intent-to-treat population). FF, ﬂuticasone furoate; VI,
vilanterol.
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Efﬁcacy and safety of FF/VI once daily in COPDhigher on both days 1 and 28 for FF/VI compared with
placebo, which argues for no loss in efﬁcacy over the
4-week treatment period and hence an absence of
tolerance. It is unlikely that longer term studies with
regular treatment would detect any induction of toler-
ance, as any measurable b2 agonist-induced tolerance is
typically observed within a few days of ﬁrst dosing.
35
There are some limitations of this phase IIa study. Most
importantly, there was no end point or surrogate marker
to speciﬁcally address the relative clinical effects of FF in
COPD (such as exacerbations), whereas the observed
lung function effects are predominantly induced by the
LABA component of the combination. Related to this,
nor was VI assessed as a monotherapy. As exacerbations
are a major cause of morbidity,
36 a study with a much
larger sample size and performed over a longer period of
time is required to determine the effects of FF/VI on
exacerbation frequency. This raises the second main
limitation of this study, which is the 28-day treatment
course. Although sufﬁcient to assess the co-primary safety
end points and typical for a phase IIa study, the 28 days
of treatment in this study is not a sufﬁcient period of
time from which ﬁrm conclusions, as to the long-term
efﬁcacy of FF/VI, can be made. Another issue associated
with the ICS component of the FF/VI combination
investigated is the potential impact of ICS treatment on
the hypothalamicepituitaryeadrenal axis. Morning
urinary cortisol excretion may be decreased during ICS/
LABA therapy, and urinary cortisol excretion was not
measured in this study. Although only one dose of FF/VI
was investigated, a previous dose-ranging study investi-
gating the effect of 3, 6.25, 12.5, 25 and 50 mg of VI over
4 weeks has demonstrated a good safety and efﬁcacy
proﬁle in patients with COPD.
20 26
In conclusion, this study showed that FF/VI 400/25 mg
administered once daily by an NDPI was efﬁcacious with
a favourable safety and tolerability proﬁle. Combination
therapy in COPD is established to be an effective treat-
ment option in moderate-to-severe cases of disease, and
these results indicate that a once-daily regimen of this
combination is a possible means of addressing the
unmet needs in COPD.
Author afﬁliations
1Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden
2Department of Thoracic Medicine, Haukeland University Hospital and Institute
of Medicine, University of Bergen, Bergen, Norway
3Department of Respiratory Medicine and Allergology, Institute for Clinical
Science, Lund, Sweden
4Lung Department, St. Olavs University Hospital of Trondheim, Trondheim,
Norway
5Department of Circulation and Medical Imaging, Faculty of Medicine,
Norwegian University of Technology and Science, Trondheim, Norway
6Respiratory Medicines Development Center, GlaxoSmithKline, Research
Triangle Park, North Carolina, USA
7Respiratory Medicines Development Centre, GlaxoSmithKline, Uxbridge, UK
Acknowledgements All listed authors meet the criteria for authorship set
forth by the International Committee for Medical Journal Editors. We thank
all patients who took part in the study and the following HZC111348 study
investigators: Ragnar Dahle, M.D. (Fredrikstad, Norway), Sigbjørn Elle, M.D.
(Elverum, Norway), Per Arne Lier, M.D. (Sandvika. Norway), Bo Lundba ¨ck,
Ph.D. (Lulea, Sweden), Michael Runold, M.D., Ph.D. (Stockholm, Sweden)
and their staff. We also thank Jie Wang, M.D., Ph.D., GlaxoSmithKline Inc.,
for her contributions during protocol development and during the study.
Editorial support in the form of development of draft outline, development of
manuscript ﬁrst draft, editorial suggestions to draft versions of this paper,
assembling tables and ﬁgures, collating author comments, copyediting, fact
checking, referencing and graphic services was provided by Geoff Weller at
Gardiner-Caldwell Communications and was funded by GlaxoSmithKline. The
article-processing charge was paid by GlaxoSmithKline.
Funding This study was funded by GlaxoSmithKline, study number
HZC111348.
Competing interests JL has served as a consultant to and received lecture
fees from AstraZeneca, GlaxoSmithKline, Merck Sharpe and Dohme, Novartis
and UCB Pharma; has been partly covered by some of these companies to
attend previous scientiﬁc meetings including the ERS (European Respiratory
Society annual congress) and the AAAAI (American Academy of Allergy
Asthma and Immunology annual meeting); and has participated in clinical
research studies sponsored by AstraZeneca, GlaxoSmithKline, Merck Sharpe
and Dohme, and Novartis. PSB has received lecture fees from AstraZeneca,
GlaxoSmithKline and NycoMed; has participated in clinical research studies
sponsored by GlaxoSmithKline, Pﬁzer and Boehringer Ingelheim; and is
currently member of the Steering Committee and the Scientiﬁc Committee of
the ECLIPSE study, which is sponsored by GlaxoSmithKline. LB has served as
a consultant to and received lecture fees from AstraZeneca, GlaxoSmithKline,
Merck Sharpe and Dohme, Novartis and UCB Pharma; has been partly covered
by some of these companies to attend previous scientiﬁc meetings including
the ERS and the AAAAI; and has participated in clinical research studies
sponsored by AstraZeneca, GlaxoSmithKline, Merck Sharpe and Dohme, and
Novartis. SS has been sponsored by AstraZeneca, GlaxoSmithKline,
Boehringer Ingelheim/Pﬁzer to attend meetings and congresses including ATS
(American Thoracic Society annual meeting) and ERS; has participated in
clinical research studies sponsored by AstraZeneca, GlaxoSmithKline and
Boehringer Ingelheim; and has received lecture fees from GlaxoSmithKline and
Boehringer Ingelheim. CS-W, CC, LS, BH are employees of and hold stock in
GlaxoSmithKline.
Ethics approval Ethics approval was provided by institutional review board.
Contributors All authors developed the design and concept of the study, had
full access to and interpreted the data, and wrote the manuscript. LS, CS-W,
BH and CC approved the statistical plan. CS-W coordinated data gathering.
LS led the statistical analysis. All authors vouch for the accuracy and
completeness of the data and the data analysis. The independent steering
committee (JL, PSB, LB and SS) together with the authors employed by the
sponsor (CS-W, CC, LS and BH) had full access to the data and were
responsible for the decision to publish the paper. Employees of the sponsor
performed the statistical analysis, led by LS. The sponsor did not place any
restriction on authors about the statements made in the ﬁnal paper.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Additional data supporting the reported results and
conclusions of this study have been made available at http://datadryrad.org/
with the following doi:10.5061/dryad.7p1r30q5
Table 7 Time to patients achieving their ﬁrst instance of
$100 ml improvement in forced expiratory volume in one
second 0e4 h postdose day 1 (intent-to-treat population)
Planned relative
time, n (%)
Placebo
(N[20)
FF/VI 400/25 mg
(N[40)
5 min 2 (10) 26 (65)
15 min 2 (10) 3 (8)
30 min 3 (15) 1 (3)
1 h 0 2 (5)
2 h 1 (5) 2 (5)
4 h 2 (10) 0
Censored 10 (50) 6 (15)
Censored values are for patients who did not achieve a $100 ml
improvement 0e4 h postdose.
FF, ﬂuticasone furoate; VI, vilanterol.
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